Boehringer Ingelheim GmbH

INGELHEIM, Germany, November 16 - Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number of Satisfying Sexual Events (SSEs) and sexual desire while significantly decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).[1] Flibanserin is an investigational compound that is being developed by Boehringer Ingelheim for the treatment of pre-menopausal women with HSDD.

INGELHEIM, Germany - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting (ADA) show clinically relevant and statistically significant reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels when linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is given as add-on therapy in Type 2 diabetic patients inadequately controlled with metformin.